UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229

2018

Volltextzugriff (PDF)

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-07, Vol.373 (2), p.123-135

2015

Volltextzugriff (PDF)

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

Journal of clinical oncology, 2016-11, Vol.34 (31), p.3740-3748

2016

Volltextzugriff (PDF)

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2016-06, Vol.17 (6), p.822-835

2016

Volltextzugriff (PDF)

Omission of staging PET/CT linked to reduced survival in stage III non-small cell lung cancer: insights from the LUCAS project real-world data

Translational lung cancer research, 2024-07, Vol.13 (7), p.1495-1504

2024

Volltextzugriff (PDF)

An ocular lesion of unknown aetiology

Breathe (Lausanne, Switzerland), 2021-06, Vol.17 (2), p.200164-200164

2021

Volltextzugriff (PDF)

365 Tumor treating fields (TTFields, 150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) in phase 3 LUNAR Study

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A390-A390

2020

Volltextzugriff (PDF)

Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries

Current medical research and opinion, 2016-09, Vol.32 (9), p.1577-1584

2016

Volltextzugriff (PDF)

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry

Thoracic cancer, 2020-11, Vol.11 (11), p.3346-3356

2020

Volltextzugriff (PDF)

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100330-100330, Article 100330

2022

Volltextzugriff (PDF)

607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A691-A691

2023

Volltextzugriff (PDF)

Long-term control of generalized lung cancer with pembrolizumab

Onkologie (Olomouc), 2021-01, Vol.14 (Suppl.G), p.171-174

Havel, Libor

2021

Volltextzugriff (PDF)

Chemotherapy alone no longer a treatment standard for advanced non-small cell lung cancer

Onkologie (Olomouc), 2019-10, Vol.13 (5), p.221-224

Havel, Libor

2019

Volltextzugriff (PDF)

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial

Cancer treatment and research communications, 2021, Vol.28, p.100427-100427, Article 100427

2021

Volltextzugriff (PDF)

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

The lancet oncology, 2022-10, Vol.23 (10), p.1274-1286

2022

Volltextzugriff (PDF)

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7500-7500

2013

Volltextzugriff (PDF)

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-06, Vol.376 (25), p.2415-2426

2017

Volltextzugriff (PDF)

Present status and perspectives of immunotherapy in NSCLC

Onkologie (Olomouc), 2016-03, Vol.10 (1), p.26-30

Havel, Libor

2016

Volltextzugriff (PDF)

Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC

The New England journal of medicine, 2023-11, Vol.389 (21), p.1935-1948

2023

Volltextzugriff (PDF)

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Clinical cancer research, 2024-02, Vol.30 (4), p.824-835

2024

Volltextzugriff (PDF)

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

Journal of cancer research and clinical oncology, 2023-12, Vol.149 (19), p.17123-17131

2023

Volltextzugriff (PDF)

Present Experience and Perspectives of Immunotherapy of Lung Cancer

Klinická onkologie, 2015-12, Vol.28 Suppl 4 (Suppl 4), p.4S73-4S76

Havel, L

2015

Volltextzugriff (PDF)

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2024-03, Vol.42 (7), p.808-820

2024

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(71)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(28)
Humans
(20)
Oncology
(19)
Lung Cancer
(15)
Lung Neoplasms - Drug Therapy
(14)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(13)
Immunotherapy
(13)
Female
(12)
Middle Aged
(12)
Chemotherapy
(11)
Male
(11)
Aged
(10)
Respiratory System
(9)
Adult
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Cancer Therapies
(8)
Lung Neoplasms - Pathology
(8)
Patients
(8)
Carcinoma, Non-Small-Cell Lung - Pathology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Omission of staging PET/CT linked to reduced survival in stage III non-small cell lung cancer: insights from the LUCAS project real-world data

An ocular lesion of unknown aetiology

365 Tumor treating fields (TTFields, 150 kHz) concurrent with standard of care treatment for stage 4 non-small cell lung cancer (NSCLC) in phase 3 LUNAR Study

Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study

Long-term control of generalized lung cancer with pembrolizumab

Chemotherapy alone no longer a treatment standard for advanced non-small cell lung cancer

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Present status and perspectives of immunotherapy in NSCLC

Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

Present Experience and Perspectives of Immunotherapy of Lung Cancer

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer

Suchergebnisse filtern